Mouse Recombinant Protein
CAT#: TP727370
Recombinant Mouse SLAM Family Member 5/SLAMF5/CD84(C-6His)
Need it in bulk or customized? Get a free quote |
CNY 1,800.00
货期*
2周
规格
Product images
Specifications
Product Data | |
Protein Source | Human |
Expression cDNA Clone or AA Sequence |
Lys22-Pro223
|
Tag | C-His |
Buffer | Lyophilized from a 0.2 um filtered solution of PBS, pH 7.4. |
Note | Recombinant Mouse SLAM family member 5 is produced by our Mammalian expression system and the target gene encoding Lys22-Pro223 is expressed with a 6His tag at the C-terminus. |
Storage | Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
Stability | 12 months from date of despatch |
Reference Data | |
Synonyms | SLAM family member 5; Cd84; Leukocyte differentiation antigen CD84; Signaling lymphocytic activation molecule 5; CD84; Ly-9B; SLAMF5; CD84 antigen; CD84 molecule; SLAM family member 5 |
Summary | CD84, also called SLAMF5, is a member of the CD2 subgroup of the immunoglobulin receptor superfamily. Members of this CD2 subgroup mediate signal transduction through the interaction of its immunoreceptor tyrosine-based switch motifs (ITSM) in the intracellular region and the SH2 domain of adaptor molecules SAP (SLAM-associated protein) and EAT-2 (EWS-activated transcript 2), and accordingly modulate both adaptive and innate immune responses. CD84 expression has been documented on several hematopoietic cell types, including monocytes, macrophages, dendritic cells, B lymphocytes, and platelets. Activation of cell surface CD84 initiates a signaling cascade involving its intra-cytoplasmic tyrosine residues that results in Bcl-2 upregulation, which in turn enhances cell survival. Either immunoneutralization or blockade of CD84 with a CD84 extracellular domain protein fragment induces cell death in vitro and in vivo. |
Documents
FAQs |
SDS |
Customer
Reviews
Loading...